FEBRUARY 13, 2023
CARY, N.C., February 13, 2023 – Global biopharmaceutical services leader, Allucent, announced today the appointment of Lisa Benincosa, Ph.D., B.Pharm, as senior vice president of clinical pharmacology strategy. In this critical role, Benincosa will lead Allucent’s clinical pharmacology team in providing integrated drug development strategies to help Allucent’s partners optimize decision-making and create efficiencies across the drug development continuum.
“Lisa is a highly-respected industry leader who brings deep expertise in early-stage drug development and translational medicine, and extensive experience working with clients on a global scale,” said Katy Moore, president of Clinical Pharmacology and Modeling Simulation at Allucent. “Her leadership and expertise will help our team of scientists provide strategies and analyses for dose selection, assessing study designs and trial outcomes, and shaping milestone decisions – all to improve efficiencies and inform the right portfolio choices for our partners, and ultimately, help get medicines to patients faster. I’m thrilled to welcome Lisa to our A-team at Allucent.”
Highlights of Benincosa’s career to date include:
- Holding executive leadership positions in translational medicine, clinical pharmacology, drug metabolism and pharmacokinetics (DMPK), and bioanalytics at SmithKline Beecham (now GSK), Pfizer, Roche, and most recently, EMD Serono/Merck, where she served as senior vice president and global head of translational medicine.
- Building R&D expertise across diverse therapeutic areas and modalities including PROTACs, bispecifics, antibody drug conjugate (ADC), locked nucleic acid (LNA) and gene therapy.
- Receiving multiple leadership awards, including the Leadership Excellence Award from Roche pRED, the Pfizer People Leader Award, the Tribute to Women & Industry Award, and most recently the recipient of the Hartmut Derendorf Mentorship in Clinical Pharmacology award from the American College of Clinical Pharmacology (ACCP).
- Achieving numerous academic recognitions, such as being named to the West Virginia University School of Pharmacy inaugural Hall of Fame, the Willis G. Gregory Memorial Award from UB honoring outstanding alumnus, and serving on the Leadership Council at the Center for Pharmacometrics and Systems Pharmacology at the University of Florida.
“I was drawn to Allucent because I’m inspired by the opportunity to work with small and mid-sized biotechcompanies that are doing truly groundbreaking work, and am eager to use my expertise to support the discovery and development of innovative medicines for patients in need around the world,” said Benincosa. “It’s an honor to leverage my 25+ years of global leadership experience to further build Allucent’s highly talented team of scientists from across the globe, and to guide our partners in designing efficient and effective development strategies for their pioneering science.”
Benincosa received her Bachelor’s degree in Pharmacy from West Virginia University and her Ph.D. in Pharmaceutical Sciences from the University at Buffalo. She has authored more than 30 publications in peer-reviewed journals and has been an invited speaker including the David Chu lecture at the University at Buffalo, and the UCSF Schools of Pharmacy and Medicine Symposium. Benincosa is currently a Board Member of the American Society for Clinical Pharmacology & Therapeutics (ASCPT) and of Team Telomere, an advocacy organization supporting families worldwide in their battle with Dyskeratosis Congenita and related Telomere Biology Disorders.
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients. Visit Allucent.com for more information.